References
- Belpaire FM, Bogaert MG, Mugabo P, Rosseel MT. (1986). Binding to serum alpha 1-acid glycoprotein and effect of beta-adrenoceptor antagonists in rats with inflammation. Br J Pharmacol 88:697–705.
- Benet LZ, Hoener BA. (2002). Changes in plasma protein binding have little clinical relevance. Clin Pharmacol Therapeut 71:115–21.
- Bloedow DC, Hansbrough JF, Hardin T, Simons M. (1986). Postburn serum drug binding and serum protein concentrations. J Clin Pharmacol 26:147–51.
- Chu JS, Kishion S, Nomura A, Miyazaki K. (1997). Serum alpha 1-acid glycoprotein, sialic acid, and protein binding of disopyramide in normal subjects and cardiac patients. Acta Pharmacol Sin 18:408–10.
- Ebihara T, Nishihara M, Takahashi J, et al. (2018). Differences in nonclinical pharmacokinetics between species and prediction of human pharmacokinetics of TAK-272 (SCO-272), a novel orally active renin inhibitor. Biopharm Drug Dispos 39:175–83.
- Grossman SH, Davis D, Kitchell BB, et al. (1982). Diazepam and lidocaine plasma protein binding in renal disease. Clin Pharmacol Therapeut 31:350–7.
- Huang Z, Ung T. (2013). Effect of alpha-1-acid glycoprotein binding on pharmacokinetics and pharmacodynamics. Curr Drug Metab 14:226–38.
- Imaeda Y, Tokuhara H, Fukase Y, et al. (2016). Discovery of TAK-272: a novel, potent, and orally active renin inhibitor. ACS Med Chem Lett 7:933–8.
- Jauregizar N, Calvo R, Suarez E, et al. (2001). Altered disposition and effect of lerisetron in rats with elevated alpha 1-acid glycoprotein levels. Pharm Res 18:838–45.
- Koiso K, Akaza H, Kikuchi K, et al. (1996). Pharmacokinetics of tamsulosin hydrochloride in patients with renal impairment: effects of alpha 1-acid glycoprotein. J Clin Pharmacol 36:1029–38.
- Kuribayashi T, Tomizawa M, Seita T, et al. (2011). Relationship between production of acute-phase proteins and strength of inflammatory stimulation in rats. Lab Animals 45:215–8.
- MacGregor GA, Markandu ND, Roulston JE, et al. (1981). Maintenance of blood pressure by the renin-angiotensin system in normal man. Nature 291:329–31.
- Matsuno K, Kuroda S, Tanaka S, et al. (2017). Safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single doses of TAK-272, a novel renin inhibitor, in healthy male subjects. Nephrol Dial Transplant 32:iii49–50. MO020.
- Murai-Kushiya M, Okada S, Kimura T, Hasegawa R. (1993). Effects of turpentine oil pretreatment on beta-blocker pharmacokinetic parameters in rats. J Pharm Pharmacol 45:836–8.
- Rodriguez M, Ortega I, Soengas I, et al. (2004). Alpha-1-acid glycoprotein directly affects the pharmacokinetics and the analgesic effect of methadone in the rat beyond protein binding. J Pharm Sci 93:2836–50.
- Roscioni SS, Heerspink HJ, de Zeeuw D. (2014). The effect of RAAS blockade on the progression of diabetic nephropathy. Nat Rev Nephrol 10:77–87.
- Routledge PA, Stargel WW, Wagner GS, Shand DG. (1980). Increased alpha-1-acid glycoprotein and lidocaine disposition in myocardial infarction. Ann Intern Med 93:701–4.
- Schmidt S, Gonzalez D, Derendorf H. (2010). Significance of protein binding in pharmacokinetics and pharmacodynamics. J Pharm Sci 99:1107–22.
- Trainor GL. (2007). The importance of plasma protein binding in drug discovery. Exp Opin Drug Discov 2:51–64.
- Yasuhara M, Fujiwara J, Kitade S, et al. (1985). Effect of altered plasma protein binding on pharmacokinetics and pharmacodynamics of propranolol in rats after surgery: role of alpha-1-acid glycoprotein. J Pharmacol Exp Therapeut 235:513–20.
- Zaman MA, Oparil S, Calhoun DA. (2002). Drugs targeting the renin-angiotensin-aldosterone system. Nat Rev Drug Discov 1:621–36.
- Zsila F, Fitos I, Bencze G, et al. (2009). Determination of human serum alpha1-acid glycoprotein and albumin binding of various marketed and preclinical kinase inhibitors. Curr Med Chem 16:1964–77.